Disc Medicine upgraded at Raymond James as bitopertin ‘uber bull case plays out’
As previously reported, Raymond James analyst Danielle Brill upgraded Disc Medicine (IRON) to Strong Buy from Outperform with a price target of ...
manilatimes11 天
Disc Medicine to Host Conference Call on End of Phase 2 FDA Meeting for Bitopertin in ...
Disc is planning to develop bitopertin as a potential treatment for a range of hematologic diseases including erythropoietic ...
C&EN20 天
Periodic Graphics: Porphyria and the vampirism myth
References used to create this graphic: Kakoullis, Loukas, Stylianos Louppides, Eleni Papachristodoulou, and George Panos. “Porphyrias and Photosensitivity: Pathophysiology for the Clinician.” ...
Seeking Alpha20 天
Disc Medicine draws but at Jefferies on lead asset
Jefferies issued a $89 price target on Disc Medicine (IRON), estimating a multi-billion dollar peak adjusted revenue opportunity for the company across erythropoietic porphyrias, myelofibrosis ...